+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Vascular Disrupting Agents Market, 2021-2030: Indications, Therapeutic Area, Molecules, Therapy, Route of Administration, and Regions

  • PDF Icon


  • 230 Pages
  • April 2021
  • Region: Global
  • Roots Analysis
  • ID: 5359105


According to the WHO, cancer is one of the leading causes of deaths worldwide, accounting for an estimated 10 million mortalities in 2020, which are projected to reach 13 million by 2030. Further, 90% of all diagnosed cancers are solid tumors  and a large number of the novel anticancer therapies are being developed for the treatment of these cancers. In the last five years, the United States Food and Drug Administration (USFDA) has approved more than 100 drugs for the treatment of different types of cancer. However, as the global population is gradually being exposed to a growing list of risk factors and cancer-causing agents, there is a pressing need for more specific and potent drugs / therapies to combat this complex, life threatening clinical condition. Given the inherent nature of solid tumors to form rapidly growing masses of malignant cells, angiogenesis and adequate blood supply is critical to the survival of the bulk tumor population. Therefore, tumor vasculature continues to be an attractive and promising therapeutic target. Vascular disrupting agents (VDAs) are therapeutic interventions that target established tumor vasculature and thereby, disrupt blood flow to cancerous tissue. 

Presently, there are multiple small molecule VDAs, which have been / are being developed for the treatment of a variety of oncological conditions, including colorectal cancer, glioblastoma, hepatocellular carcinoma, lung cancer, melanoma and ovarian cancer. Moreover, combination therapies, involving VDAs and conventional chemotherapy, radiation therapy and radioimmunotherapy, have demonstrated excellent clinical responses in multiple animal models. It is worth noting that the R&D efforts in this field are being supported by the National Institutes of Health, accounting for USD 95 million in research grants disbursed since 2016. Driven by encouraging clinical research, this niche, but emerging domain, is poised to witness healthy growth over the next decade, with pioneers in the field likely to benefit from the first-to-market advantage.

Scope of the Report

The ‘Vascular Disrupting Agents Market, 2021-2030: Distribution by Target Indications (Chemotherapy-Induced Neutropenia, Glioblastoma, Hepatocellular Carcinoma, Malignant Pleural Mesothelioma,  Non-Small Cell Lung Cancer, Prostate Cancer, Recurrent Platinum Resistant Ovarian Cancer, Transitional Cell Cancer of Renal Pelvis and Ureter),  Therapeutic Area (Hematological Malignancies, Solid Tumors and Other Therapeutic Areas), Type of Molecule (Small Molecule (Tubulin Binding Agents and Flavonoids) and Ligand-Directed Agents) and Ligand-Directed Agents), Type of Therapy (Monotherapy, Combination Therapy And Both), Route of Administration (Oral, Intravenous), and  Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World)’ report features an extensive study of the current and future potential of vascular disrupting agents, being developed for the treatment of various types of cancer. In addition, it features an elaborate discussion on the likely opportunity for the players engaged in this domain, over the next decade. 

Amongst other elements, the report includes:

  • A detailed review of the current market landscape of vascular disrupting agents, including information on phase of development (phase III, phase II / III, phase II, phase I / II, phase I, and discovery / preclinical stage) of product candidates, therapeutic area (hematological malignancies, solid tumors and others), target indication(s), type of molecule (small molecule (tubulin binding agents and flavonoids), and ligand directed agents), type of therapy (monotherapy, combination therapy and others) and route of administration (oral, intravenous and others). In addition, it presents a list of companies developing vascular disrupting agents and analysis based on year of establishment, company size and location of headquarters. 
  • Detailed profiles of the prominent players in this domain (shortlisted on the basis of number of vascular disrupting agents in development pipeline). Each profile features a brief overview of the company, its financial information (if available), detailed description (including information on the type of drug, current status of development, target indications, mode of action and type of therapy) of their respective lead drug candidates, recent developments and an informed future outlook.
  • An in-depth analysis of completed, ongoing and planned clinical studies of various vascular disrupting agents, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, enrolled patient population and regional distribution of trials, type of molecule, phase of development, study design, leading industry and non-industry players (in terms of number of trials conducted), trial focus and key indications.
  • A detailed review of more than 750 peer-reviewed, scientific articles related to research on vascular disrupting agents, which have been published during the period, 2016 - January 2021. The publications have been analyzed to highlight the trends across year of publication, emerging focus areas, popular keywords, key indications, key therapeutic areas, key research journals and popular authors. 
  • An in-depth analysis of grants awarded to various research institutes for the projects related to vascular disrupting agents, in the period between 2016 and January 2021, on the basis of parameters, such as year of award, amount awarded, administering institute center, support period, type of grant application, purpose of grant award, activity code, emerging focus areas of the grants, popular NIH departments, and type of recipient organization, while highlighting popular recipient organizations, popular program officers and regional distribution of recipient organizations.  
  • A list of key opinion leaders (KOLs) within this domain, and their assessment (based on the strength and activeness) represented in the form of 2×2 matrices. The chapter also includes a schematic world map representation (highlighting the geographical locations of eminent scientists / researchers) and an analysis evaluating the (relative) level of expertise of different KOLs, based on number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network (based on information available on ResearchGate).

One of the key objectives of the report was to estimate the existing market size and the future opportunity associated with vascular disrupting agents, over the next decade. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the evolution of the market for the period 2021-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] target indications (chemotherapy-induced neutropenia, glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma,  non-small cell lung cancer, prostate cancer, recurrent platinum resistant ovarian cancer, transitional cell cancer of renal pelvis and ureter), [B] therapeutic area (hematological malignancies, solid tumors and other therapeutic areas), [C] type of molecule (small molecule and ligand-directed agents), [D] type of therapy (monotherapy, combination therapy and both), [E] route of administration (oral, intravenous), and [F] key geographical regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World). In order to account for future uncertainties associated with the growth of targeted protein degradation market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. 

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading industry and non-industry players in this market?
  • Which cancer indications can be treated with vascular disrupting agents?
  • Which geographies are the most active in conducting clinical trials on vascular disrupting agents?
  • What is the focus area of the research activities ongoing in this domain?
  • Which are the leading administering institute centers supporting the research related to this domain?
  • Who are the key opinion leaders that can help you drive your development efforts?
  • How is the current and future market opportunity likely to be distributed across key market 

Table of Contents

1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

3.1. Chapter Overview
3.2. Overview of Vascular Disrupting Agents
3.2.1. Mechanism of Action of Vascular Disrupting Agents
3.3 Types of Vascular Disrupting Agents
3.3.1. Small Molecule Vascular Disrupting Agents Tubulin Binding Agents Flavonoids
3.3.2. Ligand Directed Vascular Disrupting Agents
3.4. Benefits of Vascular Disrupting Agents
3.5. Challenges Associated with Vascular Disrupting Agents
3.6. Future Perspectives

4.1. Chapter Overview
4.2. Vascular Disrupting Agents: Development Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Therapeutic Area
4.2.3. Analysis by Target Disease Indication
4.2.4. Analysis by Phase of Development and Target Disease Indication
4.2.5. Analysis by Type of Molecule
4.2.6. Analysis by Target Disease Indication and Type of Molecule
4.2.7. Analysis by Type of Therapy
4.2.8. Analysis by Route of Administration
4.2.9. Analysis by Potential Combination Therapeutics
4.3. Vascular Disrupting Agents: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Leading Players: Analysis by Number of Drug Candidates

5.1. Chapter Overview
5.2. AGC Biologics
5.2.1. Company Overview
5.2.2. Drug Portfolio: Vascular Disrupting Agents Drug Profile: NGR-TNF
5.2.3. Recent Developments and Future Outlook
5.3. Avid Bioservices
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Drug Portfolio: Vascular Disrupting Agents Drug Profile: Bavituximab
5.3.4. Recent Developments and Future Outlook
5.4. Bionomics
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Drug Portfolio: Vascular Disrupting Agents Drug Profile: BNC105
5.4.4. Recent Developments and Future Outlook
5.5. Mateon Therapeutics
5.5.1. Company Overview
5.5.2. Drug Portfolio: Vascular Disrupting Agents Drug Profile: CA4P Drug Profile: OXi4503
5.5.3. Recent Developments and Future Outlook
5.6. Myrexis
5.6.1. Company Overview
5.6.2. Drug Portfolio: Vascular Disrupting Agents Drug Profile: MPC-6827
5.6.3. Recent Developments and Future Outlook
5.7. VBL Therapeutics
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Drug Portfolio: Vascular Disrupting Agents Drug Profile: VB-111
5.7.4. Recent Developments and Future Outlook

6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Vascular Disrupting Agents: Clinical Trial Analysis
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Trial Registration Year and Trial Status
6.3.3. Analysis by Trial Registration Year and Number of Patients Enrolled
6.3.4. Analysis by Trial Phase
6.3.5. Analysis by Trial Phase and Number of Patients Enrolled
6.3.6. Geographical Analysis by Number of Clinical Trials
6.3.7. Geographical Analysis by Number of Patients Enrolled
6.3.8. Analysis by Study Design
6.3.9. Analysis by Trial Focus
6.3.10. Analysis by Drug Molecule
6.3.11. Analysis by Key Indications
6.3.12. Analysis by Type of Sponsor/Collaborator
6.3.13. Most Active Industry Players: Analysis by Number of Registered Trials
6.3.14. Most Active Non-Industry Players: Analysis by Number of Registered Trials

7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Vascular Disrupting Agents: List of Recent Publications
7.3.1. Analysis by Year of Publication
7.3.2. Emerging Focus Areas
7.3.3. Analysis by Popular Keywords
7.3.4. Analysis by Target Disease Indications
7.3.5. Analysis by Therapeutic Area
7.3.6. Popular Journals: Analysis by Number of Publications
7.3.7. Popular Journals: Analysis of Journal Impact Factor
7.3.8. Most Popular Authors: Analysis by Number of Publications

8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Vascular Disrupting agents: Academic Grants Analysis
8.3.1. Analysis by Year of Grant Award
8.3.2. Analysis by Amount Awarded
8.3.3. Analysis by Administering Institute Center
8.3.4. Analysis by Support Period
8.3.5. Analysis by Administering Institute Center and Support Period
8.3.6. Analysis by Type of Grant Application
8.3.7. Analysis by Activity Code
8.3.8. Word Cloud Analysis: Emerging Focus Areas
8.3.9. Popular Recipient Organizations: Analysis by Number of Grants
8.3.10. Prominent Program Officers: Analysis by Number of Grants
8.3.11. Regional Distribution of Recipient Organizations

9.1. Chapter Overview
9.2. Assumptions and Methodology
9.3. Principal Investigators of Vascular Disrupting Agents Focused Clinical Trials
9.3.1. Geographical Distribution of KOLs
9.3.2. Analysis by Type of Organization (KOL Affiliation)
9.3.3. Leading Organizations: Analysis by Number of Affiliated Principal Investigators
9.4. Prominent Key Opinion Leaders (KOLs)
9.5. KOL Benchmarking: Publisher versus Third-Party Scoring (ResearchGate Score)
9.6. Profiles of Most Active KOLs
9.6.1. KOL Profile: KOL A
9.6.2. KOL Profile: KOL B
9.6.3. KOL Profile: KOL C
9.6.4. KOL Profile: KOL D
9.6.5. KOL Profile: KOL E
9.6.6. KOL Profile: KOL F

10.1. Chapter Overview
10.2. Scope and Limitations
10.3. Key Assumptions and Forecast Methodology
10.4. Overall Vascular Disrupting Agents Market, 2021-2030
10.4.1. Vascular Disrupting Agents Market: Distribution by Target Indication
10.4.2. Vascular Disrupting Agents Market: Distribution by Therapeutic Area
10.4.3. Vascular Disrupting Agents Market: Distribution by Type of Molecule
10.4.4. Vascular Disrupting Agents Market: Distribution by Type of Therapy
10.4.5. Vascular Disrupting Agents Market: Distribution by Route of Administration
10.4.6. Vascular Disrupting Agents Market: Distribution by Geography
10.4.7. Product-wise Sales Forecast Bavituximab (Avid Bioservices) Target Patient Population Sales Forecast (USD Million) Net Present Value (USD Million) Value Creation Analysis Icaritin (Beijing Shenogen Biomedical) Target Patient Population Sales Forecast (USD Million) Net Present Value (USD Million) Value Creation Analysis NGR-TNF (AGC Biologics) Target Patient Population Sales Forecast (USD Million) Net Present Value (USD Million) Value Creation Analysis Padeliporfin (Steba biotech) Target Patient Population Sales Forecast (USD Million) Net Present Value (USD Million) Value Creation Analysis Plinabulin (BeyondSpring Pharmaceuticals) Target Patient Population Sales Forecast (USD Million) Net Present Value (USD Million) Value Creation Analysis VB-111 (VBL Therapeutics) Target Patient Population Sales Forecast (USD Million) Net Present Value (USD Million) Value Creation Analysis


Companies Mentioned

  • AbbVie
  • Abramson Cancer Center
  • Academy of Military Medical Sciences
  • AIDS Malignancy Consortium
  • Amgen
  • Anhui Provincial Hospital
  • Argonaut Manufacturing Services
  • Asan Medical Center
  • Asian Myeloid Working Group
  • Atlantic Urology Clinics
  • Austin Health
  • Avid Bioservices (formerly known as Peregrine Pharmaceuticals)
  • Barbara Ann Karmanos Cancer Institute
  • Basilea Pharmaceutica
  • Beijing Cancer Hospital
  • Beijing Chaoyang Hospital
  • Beijing Shenogen Pharmaceutical
  • BeyondSpring
  • Bionomics
  • Brigham and Women's Hospital
  • Cancer Treatment Centers of America
  • Carle Cancer Institute
  • Case Comprehensive Cancer Center (Case CCC)
  • Case Western Reserve University
  • Celgene (acquired by Bristol Myers Squibb)
  • China University of Petroleum-Beijing (CUP)
  • Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
  • Chong Kun Dang Pharmaceutical
  • Cleveland Clinic
  • Columbia University Health Sciences
  • Dana-Farber Cancer Institute
  • Dartmouth College
  • Dartmouth-Hitchcock Medical Center
  • Dresden University of Technology (TUD)
  • Duke Cancer Institute
  • Duke University
  • Emory University
  • EpiCept
  • Fennec Pharmaceuticals
  • First Affiliated Hospital of Harbin Medical University
  • First Affiliated Hospital of Xi'an Jiaotong University (formerly known as the The First Affiliated Hospital of Xi’an Medical University)
  • Fox Chase Cancer Center
  • Froedtert & the Medical College of Wisconsin
  • Fudan University
  • Fudan University Shanghai Cancer Center (FUSCC)
  • Fujian Provincial Cancer Hospital
  • Guangxi University
  • H. Lee Moffitt Cancer Center and Research Institute
  • Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut
  • Henan Provincial People's Hospital
  • Henry Ford Health System
  • Hospital Universitario Clínico San Carlos
  • Hunan Cancer Hospital
  • Iceni Pharmaceuticals
  • Incanthera
  • Institute of Hematology and Blood Diseases Hospital (IH)
  • Jilin Provincial Cancer Hospital (JPCH)
  • Jinzhou Medical University
  • Kepler University Hospital
  • Krankenhaus der Barmherzigen Schwestern
  • Linyi Cancer Hospital
  • Madrigal Pharmaceuticals
  • Marshfield Clinic Health System
  • Massachusetts General Hospital
  • Mateon Therapeutics
  • Mayo Clinic
  • MediciNova
  • Memorial Sloan Kettering Cancer Center
  • Millennium Pharmaceuticals
  • Moffitt Cancer Center
  • MolMed (acquired by AGC Biologics)
  • Multiple Myeloma Research Consortium (MMRC)
  • Myrexis
  • Nanfang Hospital of Southern Medical University (NFYY)
  • Nanjing Medical University
  • Nanjing Sanhome Pharmaceutical
  • NanoCarrier
  • National Cancer Institute
  • National University Hospital (NUH)
  • NIH Clinical Center
  • Northwell Health
  • Northwestern University Feinberg School of Medicine
  • Novartis
  • O’Neal Comprehensive Care Center at UAB
  • Ochsner Medical Center
  • Oregon Health & Science University (OHSU)
  • Paracelsus Medical University Salzburg
  • Parc Taulí
  • Parkview Cancer Institute
  • Peking Union Medical College Hospital
  • Peking University Health Science Center
  • People’s Liberation Army (PLA) 81 Hospital
  • PharmaMar
  • Poznan University of Medical Sciences (PUMS)
  • Premier Gynecologic Oncology
  • Qilu Hospital of Shandong University
  • Rankweil Hospital
  • Ruijin Hospital
  • Rutgers Cancer Institute of New Jersey
  • Rutgers New Jersey Medical School
  • San Raffaele Hospital
  • Sanford Health
  • Sanofi Genzyme
  • Shanghai Changzheng Hospital
  • Shanghai Jiao Tong University
  • Shenyang Sixth People's Hospital
  • Sichuan Industrial Institute of Antibiotics (SIIA)
  • SP ZOZ Ministerstwa Spraw Wewnętrznych z Warmińsko – Mazurskim Centrum Onkologii
  • St. Joseph Medical Center
  • St. Luke's University Health Network (SLUHN)
  • St. Vincent Gynecologic Oncology
  • Steba biotech
  • Sylvester Comprehensive Cancer Center
  • SynCore Biotechnology
  • Takeda
  • Teva Pharmaceutical Industries
  • Texas Oncology-Austin Central
  • The First Affiliated Hospital of Anhui Medical University
  • The First Affiliated Hospital with Nanjing Medical University
  • The First Hospital of China Medical University
  • The First Hospital of Jilin University
  • The First People's Hospital of Foshan
  • The Johns Hopkins Hospital
  • The Second Affiliated Hospital of Zhejiang University School of Medicine (SAHZU)
  • The Sixth Affiliated Hospital of Sun Yat-sen University
  • The Third Xiangya Hospital of Central South University
  • The University of Texas MD Anderson Cancer Center
  • Tianjin Medical University Cancer Institute and Hospital (TMUCIH)
  • Tongji Hospital
  • UAB Division of GYN Oncology
  • UAMS Myeloma Center
  • UCLA Jonsson Comprehensive Cancer Center
  • University College London
  • University Hospital of Clermont-Ferrand
  • University Hospital Würzburg
  • University of Arizona Cancer Center
  • University of Arkansas
  • University of California, Irvine (UCI)
  • University of Chicago
  • University of Cincinnati
  • University of Colorado Denver
  • University of Illinois at Chicago
  • University of Iowa
  • University of Kansas Cancer Center
  • University of Kentucky
  • University of Minnesota
  • University of New Mexico
  • University Of North Carolina at Chapel Hill
  • University of Texas Health Science Center
  • University of Vermont
  • University of Wisconsin
  • UPMC Hillman Cancer Center
  • UT Southwestern Medical Center
  • VBL Therapeutics
  • Virgen del Rocío University Hospital
  • Wake Forest Baptist Medical Center
  • Wake Forest School of Medicine
  • West Penn Hospital
  • Wilhelminenspital Vienna
  • Wilmot Cancer Institute
  • Wistar Institute
  • Yunnan Provincial Hospital of Traditional Chinese Medicine
  • Zhongshan Hospital, Fudan University